Active Biotech AB presents exploratory data from ANYARA project
Do you know when to trade ATVBF ?
Biotechnology company Active Biotech AB (NASDAQ OMX Nordic:ACTI) said on Wednesday that it has presented exploratory data from its ANYARA project at the Keystone Symposia "Molecular and Cellular Biology of Immune Escape in Cancer" held in Keystone, Colorado.
The drug candidate ANYARA, using TTS technology, is currently in pivotal Phase III clinical trials for renal cell cancer.
Study results demonstrate that TTS therapy can be further enhanced by specifically modulating the immune response in this experimental model, Active Biotech said.
Comments on this story may be sent to admin@m2.com
For full details on (ATVBF) ATVBF. (ATVBF) has Short Term PowerRatings at TradingMarkets. Details on (ATVBF) Short Term PowerRatings is available at This Link.
- Evotec signs agreement with Active Biotech - 03/11/10
- Evotec and Active Biotech announce partnership on small molecule modulators - 03/11/10
- Evotec Signs High Throughput Screening Agreement With Active Biotech - 03/11/10
- Evotec Signs High Throughput Screening Agreement with Active Biotech - 03/11/10
- Active Biotech AB reports change in shares and votes after exercise of employee stock options - 02/26/10
- More News >>


